scholarly journals Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2747 ◽  
Author(s):  
Lara Mussolin ◽  
Marié-Cecilé Le Deley ◽  
Elisa Carraro ◽  
Christine Damm-Welk ◽  
Andishe Attarbaschi ◽  
...  
Keyword(s):  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Risk Group ◽  
Large Cell ◽  
Hazard Ratio ◽  
Long Term Results ◽  
Molecular Characteristics ◽  
Risk Of Failure ◽  
Large Cell Lymphoma

With the aim of describing the long-term follow-up and to define the prognostic role of the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 years homogeneously treated within the international ALCL99 trial. The 10-year progression free survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological characteristics, only patients presenting a small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure (hazard ratio = 2.49). Analysis of minimal disseminated disease (MDD), available for 162 patients, showed that both SC/LH pattern (hazard ratio = 2.4) and MDD positivity (hazard ratio = 2.15) were significantly associated with risk of failure in multivariate analysis. Considering MDD and SC/LH results, patients were separated into three biological/pathological (bp) risk groups: a high-risk group (bpHR) including MDD-positive patients with SC/LH pattern; a low-risk group (bpLR) including MDD-negative patients without SC/LH pattern; and an intermediate-risk group (bpIR) including remaining patients. The 10-year PFS was 40%, 75% and 86% for bpHR, bpIR and bpLR, respectively (p < 0.0001). These results should be considered in the design of future ALCL trials to tailor individual treatments.

Long-Term Outcome of Adults With Systemic Anaplastic Large-Cell Lymphoma Treated Within the Groupe d'Étude des Lymphomes de l'Adulte Trials

2012 ◽  
Vol 30 (32) ◽  
pp. 3939-3946 ◽  
Author(s):  
David Sibon ◽  
Marion Fournier ◽  
Josette Brière ◽  
Laurence Lamant ◽  
Corinne Haioun ◽  
...  
Keyword(s):  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
International Prognostic Index ◽  
Large Cell ◽  
Long Term Outcome ◽  
Anaplastic Lymphoma ◽  
Long Term Study ◽  
Large Cell Lymphoma ◽  
Alk Positive

Purpose Systemic anaplastic large-cell lymphoma (ALCL) is a T-cell lymphoma, whose anaplastic lymphoma kinase (ALK) expression varies according to age. Long-term outcomes of chemotherapy-treated adults are not definitively established and should be evaluated. Patients and Methods Patients treated in three Groupe d'Étude des Lymphomes de l'Adulte prospective clinical trials with confirmed systemic ALCL after immunohistopathologic review and defined ALK expression status were analyzed. Results Among the 138 adult patients with ALCL, 64 (46%) were ALK positive, and 74 (54%) were ALK negative. Median follow-up was 8 years. At diagnosis, significantly more patients younger than 40 years old were ALK positive than ALK negative (66% v 23%, respectively; P < .001). Comparing patients with ALK-positive and ALK-negative ALCL, β2-microglobulin was ≥ 3 mg/L in 12% and 33% (P = .017); International Prognostic Index was high (score, 3 to 5) in 23% and 48% (P = .03); complete response rates to first-line treatment were 86% and 68% (P = .01); and 8-year overall survival (OS) rates were 82% (95% CI, 69% to 89%) and 49% (95% CI, 37% to 61%), respectively (P < .001). The survival difference mostly affected patients age ≥ 40 years. Multivariate analysis identified β2-microglobulin ≥ 3 mg/L (P < .001) and age ≥ 40 years (P = .029), but not ALK status, as prognostic for OS. These two variables distinguished four survival risk groups, with 8-year OS ranging from 84% to 22%. Conclusion Results of this long-term study enabled refinement of the prognosis of adult systemic ALCL, with ALK prognostic value dependent on age, and could provide guidance for eventual treatment adjustment.

Long-term Disease Control of Refractory Anaplastic Large Cell Lymphoma With Vinblastine

2009 ◽  
Vol 31 (2) ◽  
pp. 145-147 ◽  
Author(s):  
Rachel Garner ◽  
Ying Li ◽  
Brian Gray ◽  
Robert Zori ◽  
Raul Braylan ◽  
...  
Keyword(s):  
Disease Control ◽  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Large Cell Lymphoma

scholarly journals Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin

2021 ◽  
Vol 14 (7) ◽  
pp. e242896
Author(s):  
Appalanaidu Sasapu ◽  
Andrew L J Dunn ◽  
Jerad Gardner ◽  
Henry K Wong
Keyword(s):  
Anaplastic Large Cell Lymphoma ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Brentuximab Vedotin ◽  
Significant Heterogeneity ◽  
Antibody Drug Conjugate ◽  
Durable Response ◽  
Case Presentation ◽  
Large Cell Lymphoma

Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare non-Hodgkin’s lymphoma that arises as a single, or multiple dome-shaped tumours on the skin. The histology is characterised by the presence of atypical lymphocytes with large irregularly shaped nuclei that express the surface marker CD30. There can be significant heterogeneity in clinical manifestation and histological pattern and in rare cases accurate diagnosis can be a challenge. Here, we present an unusual case presentation of cutaneous CD30+ anaplastic large cell lymphoma with significant granulomatous histology pattern that mimicked sarcoid. After a lack of durable response to treatments that included glucocorticoid and methotrexate, targeted treatment with anti-CD30 monoclonal antibody drug conjugate (brentuximab vedotin) yielded long-term clinical remission.

Long-term survival of a child with refractory anaplastic large cell lymphoma following therapy with an antisense oligonucleotide, topotecan, and vinblastine

2011 ◽  
Vol 33 (1) ◽  
pp. 52-55
Author(s):  
Grazyna Wrobel ◽  
Radosław Chaber ◽  
Jolanta Rygier ◽  
Jolanta Bonar ◽  
Katarzyna Muszynska-Roslan ◽  
...  
Keyword(s):  
Anaplastic Large Cell Lymphoma ◽  
Antisense Oligonucleotide ◽  
Cell Lymphoma ◽  
Large Cell ◽  
Term Survival ◽  
Long Term Survival ◽  
Large Cell Lymphoma
Sign in / Sign up

Export Citation Format

Share Document